Teva $1 Billion Market Depends on New Test of Laquinimod

Teva is looking for patients with multiple sclerosis to take part in a new trial for laquinimod. The drug had previously failed to prevent relapses in clinical testing, so Teva is now exploring its efficacy in slowing the disease’s progress.
Business Week